|Dr. Jason Kelly||Co-Founder, CEO & Director||262.5k||N/A||1981|
|Dr. Reshma P. Shetty||Co-Founder, Pres, COO & Director||262.5k||N/A||1981|
|Mr. Mark E. Dmytruk||Chief Financial Officer||439.5k||N/A||1971|
|Mr. Thomas Knight Jr.||Founder||N/A||N/A||N/A|
|Mr. Austin Che||Founder, Head of Strategy & Treasurer||N/A||N/A||N/A|
|Mr. Bartholomew Canton||Founder, CTO & Sec.||N/A||N/A||N/A|
|Marie E Fallon||Chief Accounting Officer||N/A||N/A||N/A|
|Karen Tepichin||Gen. Counsel & Sec.||N/A||N/A||N/A|
|Ms. Anna Marie Wagner||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Ms. Samantha Sutton||Head of People||N/A||N/A||N/A|
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Ginkgo Bioworks Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.